CPT1A and neoplasm: Ongoing clinical trials investigating strategies to improve anti-ErbB2 mAb therapy, such as ex vivo activated allogenic NK cells or macrophages engineered to express an anti-ErbB2 chimeric antigen receptor (CAR-M), may benefit from the enhanced anti-tumor immune responses induced by Cpt1a inhibition, potentially improving outcomes for tumors evading ADCC and resistant to Trastuzumab87,88.